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Background: Studies in animals showed that PCSK9 is involved in HDL metabolism. We investigated the molecular
mechanism by which PCSK9 regulates HDL cholesterol concentration and also whether Pcsk9 inactivation might
affect cholesterol efflux capacity of serum and atherosclerotic fatty streak volume.
Methods: Mass spectrometry and western blot were used to analyze the level of apolipoprotein E (APOE) and A1
(APOA1). A mouse model overexpressing human LDLR was used to test the effect of high levels of liver LDLR on
the concentration of HDL cholesterol and APOE-containing HDL subfractions. Pcsk9 knockout males lacking LDLR
and APOE were used to test whether LDLR and APOE are necessary for PCSK9-mediated HDL cholesterol regulation.
We also investigated the effects of Pcsk9 inactivation on cholesterol efflux capacity of serum using THP-1 and J774.
A1 macrophage foam cells and atherosclerotic fatty streak volume in the aortic sinus of Pcsk9 knockout males fed
an atherogenic diet.
Results: APOE and APOA1 were reduced in the same HDL subfractions of Pcsk9 knockout and human LDLR
transgenic male mice. In Pcsk9/Ldlr double-knockout mice, HDL cholesterol concentration was lower than in Ldlr
knockout mice and higher than in wild-type controls. In Pcsk9/Apoe double-knockout mice, HDL cholesterol
concentration was similar to that of Apoe knockout males. In Pcsk9 knockout males, THP-1 macrophage cholesterol
efflux capacity of serum was reduced and the fatty streak lesion volume was similar to wild-type controls.
Conclusions: In mice, LDLR and APOE are important factors for PCSK9-mediated HDL regulation. Our data suggest that,
although LDLR plays a major role in PCSK9-mediated regulation of HDL cholesterol concentration, it is not the only
mechanism and that, regardless of mechanism, APOE is essential. Pcsk9 inactivation decreases the HDL cholesterol
concentration and cholesterol efflux capacity in serum, but does not increase atherosclerotic fatty streak volume.
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Proprotein convertase subtilisin/kexin type 9Background
PCSK9 is a member of the proprotein convertase subtili-
sin/kexin family. Mutations in PCSK9 have been identified
in familial autosomal dominant hypercholesterolemia pa-
tients, and gain-of-function mutations increase LDL chol-
esterol concentration [1,2]. The major molecular function* Correspondence: ron.korstanje@jax.org
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reproduction in any medium, provided the orof PCSK9 in LDL cholesterol and lipid homeostasis is deg-
radation of the LDL receptor (LDLR), VLDL receptor
(VLDLR) and LDLR-related protein 8 (LRP8) [3-5]. In
addition, several studies in mice and non-human primates
have shown that PCSK9 is involved in HDL metabolism.
Pcsk9 KO male mice on a B6 background fed a chow diet
exhibited a 30% reduction in HDL cholesterol concentra-
tion [6]. B6 male mice fed a high fat diet and then treated
with a Pcsk9 antisense oligonucleotide inhibitor for 6 weeks
showed a 54% reduction in HDL cholesterol concentra-
tion [7]. In male cynomolgus macaques, treatment withd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 HDL cholesterol concentrations in control and Pcsk9
KO males and females. Plasma was obtained from male and
female mice (n > 10 per genotype) fed a normal chow diet from
weaning until 8 weeks of age and then an atherogenic diet until
16 weeks of age. Data represent the mean ± SEM. *P < 0.05,
†P < 0.001, ‡P < 0.0001.
Choi et al. Lipids in Health and Disease 2013, 12:112 Page 2 of 10
http://www.lipidworld.com/content/12/1/112neutralizing antibodies against PCSK9 reduced HDL chol-
esterol concentrations for the first seven days of treatment
[8]. Despite the accumulating evidence, the molecular
mechanism by which PCSK9 regulates HDL cholesterol
concentration has not been investigated. Previous studies
reported decreased levels of circulating APOE and higher
levels of LDLR, VLDLR, and LRP8 by PCSK9 inhibition
[4-6]. APOE in lipoproteins acts as a ligand of LDLR family
proteins and promotes lipoprotein particle clearance [9,10].
APOE is an efficient cholesterol acceptor in HDL, and the
binding of APOE in newly secreted HDL (also called nas-
cent HDL) increases the particle size and cholesterol con-
centration [11,12]. Thus, PCSK9-mediated regulation of
APOE levels in HDL may be a key mechanism that deter-
mines HDL cholesterol concentration. In this study, we
show that increased LDLR decreases APOE-containing
HDL subfractions and HDL cholesterol concentrations in
mice. We further demonstrate that, although LDLR plays
an important role in PCSK9-mediated regulation of HDL
cholesterol concentration, PCSK9 does not entirely rely on
LDLR and that PCSK9-mediated regulation of HDL choles-
terol concentration relies entirely on the presence of APOE.
Finally, we show that, although Pcsk9 KO reduces HDL
cholesterol concentration and cholesterol efflux capacity in
serum, there is no significant impact on early atherogenesis.
Results
PCSK9-mediated HDL cholesterol regulation is partially
sex- and diet-dependent
To validate the effect of PCSK9 on the regulation of HDL
cholesterol concentration, we compared HDL cholesterol
concentrations in Pcsk9 KO and control males and females
on a chow diet and an atherogenic diet (Figure 1). Com-
pared to control mice, all Pcsk9 KO mice had lower HDL
cholesterol concentrations. In Pcsk9 KO males, concentra-
tions were decreased by 47% on a chow diet (KO, 42.1 ±
1.3 mg/dl; control, 79.2 ± 1.9 mg/dl; P < 0.0001) and by
21% on an atherogenic diet (KO, 79.2 ± 4.0 mg/dl; control,
100.6 ± 3.5 mg/dl; P < 0.001). In Pcsk9 KO females, con-
centrations were decreased by 37% on a chow diet (KO,
37.8 ± 0.9 mg/dl; control, 59.7 ± 1.7 mg/dl; P < 0.0001) and
by 17% on an atherogenic diet (KO, 68.4 ± 2.1 mg/dl; con-
trol, 82.8 ± 3.8 mg/dl; P < 0.05). Also, the differences in
HDL cholesterol concentrations between Pcsk9 KO mice
and controls were smaller in mice fed the atherogenic diet
than in mice fed the chow diet. These results indicate that
PCSK9-mediated regulation of HDL cholesterol concen-
trations is partially dependent on sex and diet.
APOE in non-HDL depleted serum (NHDS) is significantly
reduced in Pcsk9 KO mice
To investigate how PCSK9 regulates HDL cholesterol
concentration, we examined whether APOE composition
and distribution in HDL were affected in Pcsk9 KO mice.We performed mass spectrometry using the NHDS of 8-
week-old Pcsk9 KO and control mice. The NHDS was
separated on a non-denaturing 4-30% polyacrylamide
gel that exhibited 11 bands after staining with Coomassie
Brilliant Blue R-250. Each band was excised as a 1-mm-
wide slice for mass spectrometry to identify apolipo-
proteins; results were compared between Pcsk9 KO and
control mice. As expected, APOA1, but not APOB, was
present in all bands (data not shown). The presence of
APOA1 indicated that the bands contained HDL, while
the absence of APOB indicated that APOB-containing
lipoproteins were effectively removed by the precipita-
tion method. In Pcsk9 KO mice, APOE was not found in
any bands, while in control mice, APOE was found in the
five bands with a molecular weights above 272 kDa (See
Additional file 1: Table S1). We next tested whether the
absence of APOE results from decreased APOE produc-
tion. Compared to wild-type controls, Pcsk9 KO mice
showed no decrease in Apoe expression and APOE pro-
tein level in the liver (See Additional file 2: Figure S1) and
in the peritoneal macrophages (data not shown) where
APOE is mainly produced. Combined, these results sug-
gest that the reduced APOE level in Pcsk9 KO NHDS is
not due to decreased APOE production.
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KO mice
We next investigated whether APOE reduction in the
NHDS of Pcsk9 KO was due to reduced APOE-containing
HDL subfractions. APOA1 is a hallmark of HDL, and a
reduction of APOA1 levels in serum indicates a decrease
in HDL levels. We ran NHDS of Pcsk9 KO and control
mice on 4-30% non-denaturing polyacrylamide gels and
performed western blotting for both APOE and APOA1
(Figure 2A). APOE was detected in HDL subfractions
exhibiting an apparent molecular weight larger than
272 kDa. Both APOE and APOA1 levels were severely de-
creased in the Pcsk9 KO HDL subfractions compared to
those of control mice. To quantify the levels of APOE and
APOA1, we performed SDS-PAGE and western blots. The
results showed 80–90% reduced APOE in Pcsk9 KO
NHDS (Figure 2B). The APOA1 level was 20–30% re-
duced in Pcsk9 KO serum (Figure 2C) and 30% reducedA
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Figure 2 APOE and APOA1 levels in HDL subfractions in control and
electrophoresed on non-denaturing gels and blotted using antibodies aga
SDS-PAGE and blotted using antibody against either APOE or APOA1. The
represent the mean ± SEM. * P < 0.05, ‡P < 0.0001.in pooled Pcsk9 KO NHDS compared to pooled control
NHDS (n = 3 per genotype, data not shown). These results
suggest that decreased APOE levels in Pcsk9 KO NHDS
are due to both a decrease in HDL particle numbers
(−25% APOA1) and a smaller fraction of APOE bound to
HDL particles. In the 66-kDa HDL subfraction that does
not contain APOE, APOA1 band intensity was similar be-
tween Pcsk9 KO mice and controls. Combined, our results
suggest that Pcsk9 inactivation specifically reduces APOE-
containing HDL subfractions.
Increased LDLR leads to decreased levels of HDL
cholesterol concentration and APOE-containing
HDL subfractions
We investigated the molecular mechanism behind the
reduced level of APOE-containing HDL in Pcsk9 KO
mice. We hypothesized that LDLR is an important com-
ponent of the mechanism because LDLR is a receptor0
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is increased in Pcsk9 KO mice [6]. We thus analyzed
HDL cholesterol concentration in Tg(hLDLR) mice that
overexpress LDLR (Figure 3A). Similar to Pcsk9 KO
mice, Tg(hLDLR) mice exhibited 82% lower HDL choles-
terol concentrations compared to control mice (Tg, 14.3 ±
1.3 mg/dl; control, 79.1 ± 2.3 mg/dl; P < 0.0001). They ex-
hibited lower APOE and APOA1 levels in HDL sub-
fractions larger than the molecular weight of 272 kDa
(Figure 3B). Distribution of APOA1 in NHDS of Tg
(hLDLR) controls was different from that of Pcsk9 KO con-
trols, which is likely due to the mixed genetic background
(SJL/J and C57BL/6 J) of the Tg(hLDLR) controls vs. the
C57BL/6 J background of the Pcsk9 KO controls. The drop
in APOE (80–90%) (Figure 3C) and APOA1 (53%) (n = 3
per genotype, data not shown) was further confirmed by
western blot analysis of NHDS. These results confirmedA
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Figure 3 HDL cholesterol concentrations in serum, APOE and APOA1
and NHDS were obtained from serum of 8-week-old males (n = 5 per geno
(hLDLR) mice (A). HDL subfractions were electrophoresed in a non-denatur
μg of proteins of NHDS were separated by SDS-PAGE and blotted using an
Data represent the mean ± SEM. †P < 0.001.that LDLR overexpression in mice reduces the concentra-
tions of HDL cholesterol and APOE-containing HDL.
PCSK9 regulates HDL cholesterol concentration through
LDLR and APOE
We verified whether LDLR was the unique receptor for
the PCSK9-mediated HDL regulation by measuring HDL
cholesterol concentrations in Ldlr KO, Pcsk9/Ldlr double-
KO and wild-type control mice (Figure 4). HDL choles-
terol concentrations in Ldlr KO were 1.6-fold higher than
in wild-type control mice (145.6 ± 4.1 mg/dl vs 90.3 ±
3.4 mg/dl, P < 0.001). However, the absence of PCSK9
combined with the absence of LDLR resulted in a 1.2-fold
induction of HDL cholesterol levels (115.5 ± 4.5 mg/dl vs
90.3 ± 3.4 mg/dl, P < 0.001), indicating that PCSK9 does
not completely rely on an LDLR-dependent mechanism to
regulate HDL cholesterol concentration.)
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Figure 4 Effect of PCSK9 on HDL cholesterol concentration in
mice having a wild-type control, Ldlr KO or Apoe KO
background. Fasting plasma samples were obtained from 3-month-
old mice (n = 5 per genotype) fed a normal chow diet. HDL
cholesterol concentrations were measured in mice that expressed
normal endogenous PCSK9 (white control bars) or were deficient in
PCSK9 (black bars). Data represent the mean ± SEM. ‡P < 0.0001.
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Figure 5 ABCA1 level in livers from control and Pcsk9 KO mice.
The whole liver was obtained from 8-week-old control and Pcsk9 KO
males (n = 5 per genotype). One hundred μg of proteins were separated
by SDS-PAGE and blotted using antibody against ABCA1. ABCA1 level
was normalized by β actin. Data represent the mean ± SEM.
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mediated HDL regulation. HDL cholesterol concentrations
were measured in Apoe KO and Pcsk9/Apoe double-KO
males and were found similar (101.6 ± 7.0 mg/dl vs 99.9 ±
4.5 mg/dl). These results indicate that PCSK9-mediated
HDL regulation — either LDLR-dependent or LDLR-
independent — completely relies on APOE.
Scavenger receptors type 1 (SR-B1) is an important
factor for HDL clearances in mice [14,15], however two
recent publications reported no relationship between
SR-B1 and PCSK9. Rashid et al., stated that SR-B1 level
is not changed in Pcsk9 knockout mouse livers [6] and
Lalanne et. al., showed that adenoviral PCSK9 transduc-
tion in C57BL/6 mice does not change SR-B1 level in
livers [16]. In addition to SR-B1, ATP-binding cassette
transporter A1 (ABCA1) plays an important role for
maintaining circulating HDL cholesterol concentrations
through APOA1 and APOE-dependent efflux [17], we
tested whether ABCA1 level is changed in Pcsk9 KO
mouse livers and found no difference in ABCA1 level
betweenWTcontrols and Pcsk9 KOmouse livers (Figure 5).
Taken together, no change of SR-B1 and ABCA1 levels
in Pcsk9 KO mouse livers support that reduced HDL
cholesterol concentration in Pcsk9 KO mouse serum is
largely through the clearance of APOE-containing HDL
subfractions.Effects of Pcsk9 inactivation on the cholesterol efflux
capacity of serum and atherosclerotic fatty streak volume
in aortic sinus
To test whether Pcsk9 inactivation affects cholesterol ef-
flux capacity of serum, macrophage foam cell formation
was induced and cells were treated with mouse serum as
previously described [18]. The amount of a fluorescent
cholesterol mimic present in cells and released in the cul-
ture media was then measured. Two lines of macrophages
were tested, the human THP-1 and mouse J774A.1 cells.
In THP-1 cells, incubation with Pcsk9 KO serum resulted
in significant lower cholesterol efflux capacity than with
control serum (Figure 6A). Slower and very small reduc-
tion of cholesterol efflux in J774.A1 cells than in THP-1
cells is likely due to deficient APOE secretion (Figure 6B)
[19]. As inefficient cholesterol removal from lesions in-
creases the atherosclerotic burden [20], we tested whether
early atherogenesis is increased by measuring fatty streak
volume in Pcsk9 KO mice. We compared atherosclerotic
fatty streak volume in 34-week-old Pcsk9 KO and control
males after a 10-week atherogenic diet. The fatty streaks
in the same 240-μm region of the aortic sinus were visual-
ized by oil red O staining (Figure 7A) and then digitalized
and reconstructed in 3D images (Figure 7B). Compared to
controls, the fatty streak volume in Pcsk9 KO mice was
similar (Figure 7C) while HDL cholesterol concentration
5
10
15
20
10
15
20
25
Untreated  Control serum KO serum
*
*
BA
 C
ho
le
st
er
ol
 e
ffl
ux
 c
ap
ac
ity
  
fr
om
 J
77
4A
.1
 (
%
)
fr
om
 T
H
P
-1
 (
%
)
C
ho
le
st
er
ol
 e
ffl
ux
 c
ap
ac
ity
  
Pcsk9
Figure 6 Cholesterol efflux capacity in control and Pcsk9 KO serum. Cholesterol efflux capacity (%) was calculated as F-cholesterol efflux
(%) = F-cholesterol in medium / (F-cholesterol in medium+ F-cholesterol in cells) × 100. Cholesterol efflux was induced by 5 μl serum incubation in
triplicate (n = 5 per genotype) in THP-1 for 1 hour (A) and J774A.1 macrophage foam cells for 48 hours (B). Data represent the mean ± SEM. *P < 0.05.
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http://www.lipidworld.com/content/12/1/112was 24% lower (KO, 73.5 ± 7.5 mg/dl; control, 97.1 ±
5.2 mg/dl; P < 0.05). Altogether, these results suggest that
although the cholesterol efflux capacity of Pcsk9 KO serum
from THP-1 macrophage foam cells is reduced, Pcsk9
inactivation does not have a measurable impact on early
atherogenesis under our experimental conditions.Discussion
In this study, we revealed the molecular mechanism by
which PCSK9 controls HDL cholesterol concentration
by regulating the APOE-containing HDL. We show that
APOE and APOA1 in the same size of HDL subfractions
were reduced in Pcsk9 KO mice. Combined with the re-
sult showing no impact on smaller 66-kDa sized HDL
level, our data suggest that PCSK9 specifically controls
APOE-containing HDL.AO
AO
CA
CA
KO
A
0.5 mm
0.5 mm
0.5 mm
Control
B
Pcsk9
0.5 mm
3D recooil-red O
Figure 7 Atherosclerotic fatty streak volume in control and Pcsk9 KO
were fed an atherogenic diet for 10 weeks. Aortic sections were stained wi
was reconstructed (B) and the fatty streak volume (mm3) quantified in 240Because APOE-containing lipoproteins are mainly cleared
via LDLR [10,21] and Pcsk9 KO mice exhibiting 2- to 3-fold
higher levels of LDLR in the liver [6,22], we hypothesized
that rapid clearance of APOE-containing HDL via LDLR
might be the major cause of decreased HDL cholesterol
concentration in Pcsk9 KO mice. This hypothesis was rein-
forced by the analysis of Tg(hLDLR) mice that overexpress
LDLR. They exhibit very low levels of APOE-containing
HDL, and their HDL cholesterol concentrations are re-
duced by 82% (versus about 47% in Pcsk9 KO mice). Be-
cause APOE is known to promote cholesterol loading on
HDL [11], this dramatic 82% reduction likely reflects a
lower HDL cholesterol concentration due to the faster
clearance of the APOE-containing HDL and the poor cho-
lesterol concentration in the remaining smaller lipid-free or
lipid-poor HDL subfraction. Our data clearly points at the
key role of LDLR in the clearance of HDL.   
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role in PCSK9-mediated HDL cholesterol regulation, it
is not a unique factor implicated in this process. HDL
cholesterol concentrations in Pcsk9/Ldlr double-KO mice
were 21% lower than in Ldlr KO mice, revealing an LDLR-
independent effect of PCSK9. No change of ABCA1 and
SR-B1 levels in Pcsk9 KO mouse livers support that re-
duced HDL cholesterol concentration in Pcsk9 KO mouse
serum is largely through the clearance of APOE-containing
HDL subfractions. A possible LDLR-independent mechan-
ism may be based on APOE binding to the VLDLR, as
APOE is an efficient ligand of VLDLR. VLDLR is targeted
for degradation by PCSK9 in HEK293 and NIH 3 T3 cell
lines [4], and cell surface VLDLR levels were increased in
the adipose tissue of Pcsk9 KO mice [5]. We finally show
that HDL cholesterol concentrations are similar between
Apoe KO and Pcsk9/Apoe double-KO males, suggesting
that the PCSK9-mediated HDL cholesterol regulation is
dependent on the presence of APOE and that the role of
APOE entirely depends on its ability to mediate the bind-
ing of HDL to LDLR or VLDLR.
Therapeutic inhibition of PCSK9 is a promising pro-
atherogenic LDL cholesterol-lowering treatment. Co-
treatment of PCSK9 inhibitors with drugs that suppress
cholesterol synthesis is even more effective in reducing
LDL cholesterol in hypercholesterolemia patients [23-25].
Inconsistent with recent clinical trials, studies in laboratory
animals show that PCSK9 inhibition reduces HDL choles-
terol concentration. The inconsistency might be due to dif-
ferent dosage of PCSK9 inhibition in different studies. Or,
a reduction in HDL cholesterol concentration by PCSK9
inhibition might be restricted to species such as the mouse
in which APOE-containing HDL level is elevated, com-
pared to human [26-28].
Independently of the level of HDL cholesterol concen-
tration, cholesterol efflux capacity is associated with ath-
erosclerotic plaque formation in the coronary arteries [20].
We found that Pcsk9 KO leads to a reduction inTable 1 Descriptions of mice used in this study
Mouse strain
Abbreviation Full name, descripti
Apoa1 KO B6;129P2-Apoa1tm1Unc/J (JAX® 002055)
Apoe KO B6.129P2-Apoetm1Unc/J (JAX® 002052) backcros
Tg(hLDLR) Hemizygous male offspring of hemizygous B6;SJL
(JAX® #008850) males mated with B6SJLF1/J (JAX
Ldlr KO B6.129S7-Ldlrtm1Her/J (JAX® 002207) backcrosse
Pcsk9 KO B6;129S6-Pcsk9tm1Jdh/J (JAX® 005993) backcros
Pcsk9 KO IRCM B6 mice that lack the Pcsk9 proximal promote
Pcsk9/Apoe double-KO Apoe KO mice crossed to Pcsk9 KO IRCM mice
Pcsk9/Ldlr double-KO Ldlr KO mice crossed to Pcsk9 KO IRCM mice
C57BL/6 J is JAX® 000664.cholesterol efflux capacity of serum from THP-1 macro-
phage foam cells, but there was no significant impact on
atherogenic-diet induced fatty streak volume in aortic sinus.
Similar observation was made in a recent study showing no
increase of atherosclerotic lesion size in the aortas of Pcsk9/
Ldlr double-KO and Pcsk9/Apoe double-KO mice. We
speculate that this might be because Pcsk9 inactivation re-
duces pro-atherogenic LDL level in the circulation and also
reduces the accumulation of esterified cholesterol in the
aortas [29].
Conclusions
In mice, PCSK9 controls circulating cholesterol con-
centrations by regulating both LDL and HDL levels
through LDLR. Our data suggest that the regulation
of HDL by PCSK9 is mainly through LDLR-mediated
APOE-containing HDL clearance and that other targets
of PCSK9 might be involved in the process [5,30]. Our
data validate that reduced HDL cholesterol concentra-
tion and cholesterol efflux capacity in serum by Pcsk9
inactivation do not have significant impact on the early
stage of atherosclerosis development.
Methods
Mice, husbandry and diet
Eight different strains of mice plus two types of control
mice were used in this study (Table 1). Mice were main-
tained in a pathogen-free and climate-controlled facility
with a 12-hour light/dark cycle and fed ad libitum through-
out the experiment. Pcsk9 KO, Tg(hLDLR) and their con-
trol mice were fed a normal chow diet containing 6% fat
(5 K52 LabDiet®, PMI Nutrition International, St. Louis,
MO). At eight weeks of age, a group of Pcsk9 KO and
control mice were switched to an atherogenic diet until
16 weeks of age (18.5% dietary fat, 1.9% corn oil, 50%
sucrose, 4.1% cellulose, 20% casein, 1% cholesterol, 0.5%
cholic acid, 5% mineral mix, 1% vitamin mix, 0.3% DL-
methione, 0.13% DL-a-tochopherol, 1% choline chlorideControl mice
on
C57BL/6 J
sed to B6 C57BL/6 J
-Tg(Mt1-LDLR)93-4Reh/AgnJ
® #100012) females
Wild-type male littermates of Tg(hLDLR)
d to B6 C57BL/6 J
sed to B6 C57BL/6 J
r and exon 1 region C57BL/6 J
C57BL/6 J
C57BL/6 J
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fed the same atherogenic diet between 24 and 34 weeks of
age. Pcsk9/Ldlr double-KO, Pcsk9/Apoe double-KO, Pcsk9
KO IRCM, Ldlr KO, Apoe KO, wild-type control mice
were fed a regular diet containing 6% fat (2018 Teklad
Global) diet until three months of age [29]. Experiments
were approved by the Institutional Animal Care and Use
Committee of The Jackson Laboratory, Bar Harbor, ME
and by the Animal Care Committee of The Institute de
Recherches Cliniques de Montréal (IRCM), Montreal, QC.
HDL cholesterol measurement
At 8 and 16 weeks of age, mice were fasted from 07:00 am
to 11:00 am and then retro-orbitally bled; 100–150 μl of
blood was collected in a 1.5 ml tube for serum and in a
1.5 ml tube containing 5 μl of 200 μM ethylenediamine-
tetraacetic acid (EDTA) for plasma. Serum or plasma was
isolated by centrifugation at 15,000 rpm for five minutes
at room temperature within two hours of the bleed. Col-
lected supernatant was stored at −20°C until the HDL
cholesterol concentration was measured by the HDLD
assay, using an enzymatic reagent kit (Beckman Coulter
Inc., Palo Alto, CA) on a Beckman Synchron DXC
(Beckman Coulter Inc., Palo Alto, CA). The HDL method
used for HDLD assay was validated in mice and was used
in our previous publications [32,33]. At three months of
age, plasma samples were obtained from Pcsk9/Ldlr
double-KO, Pcsk9/Apoe double-KO, Pcsk9 KO IRCM, Ldlr
KO, Apoe KO, and B6 males as previously described [29].
At 34 weeks of age, non-fasting serum HDL cholesterol
concentration was measured in the group of Pcsk9 KO
and control mice that were fed an atherogenic diet for
10 weeks [34].
Preparation of non-HDL depleted serum (NHDS) and
identification of APOE and APOA1
At eight weeks of age, mice were singly housed for four
days. Blood was collected and serum was isolated as de-
scribed above. The NHDS was collected using one-tenth
volume of the chemical precipitation reagent containing
dextran sulfate (10 g/L), magnesium ions (500 mM), and
non-reactive ingredients with sodium azide (0.1%), where
the binding of the reagent to serum precipitates the LDL
and VLDL [35]. After precipitation, the NHDS was col-
lected and then total protein concentration (μg/μl) was
determined using a Bradford assay (Sigma Life Sciences,
St. Louis, MO). Fifteen μg of proteins in NHDS were run
on a 4-30% non-denaturing polyacrylamide gradient gel
[36], and proteins bands were visualized by Coomassie
Brilliant Blue R-250. The molecular weight of the different
bands was determined using a molecular weight kit (14–
500 kDa) (Sigma Life Sciences, St. Louis, MO) according
to the manufacturer’s instructions. To identify proteins,
Coomassie Brilliant Blue R-250-stained bands were cutinto 1 mm3 cubes, proteins in each band were digested in
trypsin solution, and the tryptic peptides were subjected
to LC-MS/MS. Mass spectrometry data were collected
and MS spectra were searched against an IPI mouse pro-
tein sequence database (version 3.75) using SEQUEST
(Bioworks software, v3.3.1; Thermo Electron) [37].
Western blot
Proteins in whole liver were prepared in protein extrac-
tion buffer (T-PER reagent, Roche, Indianapolis, IN) and
a protease inhibitors cocktail tablet (Roche, Indianapolis,
IN). Fifteen μg of proteins in NHDS were electrophoresed
by SDS-PAGE or native-PAGE, and western blotting was
performed using antibodies for APOE (ab20874, poly-
clonal rabbit primary 1/1,000, Abcam, Cambridge, MA),
APOA1 (ab20453, polyclonal rabbit primary 1/1,000,
Abcam, Cambridge, MA), ABCA1 (MAB10005, monoclo-
nal mouse primary 1/750, EMD Millipore, Temecula,
CA), β actin (ab8227, polyclonal rabbit primary 1/25,000,
Abcam, Cambridge, MA) and secondary antibodies for
anti-rabbit IgG (7074S, HRP-linked secondary 1/5,000, Cell
Signaling Technology Inc., Danvers, MA) and for anti-
mouse IgG (AP308P, HRP-linked secondary 1/5,000, EMD
Millipore, Temecula, CA). Protein levels were calculated
by the protein band intensity that was obtained using
ImageJ 1.44o (National Institute of Health, Bethesda, MD).
Quantitative PCR of Apoe
Total RNA in liver was extracted using a Trizol Plus RNA
Purification kit (Invitrogen Life Technologies, Grand Is-
land, NY). Complementary DNA (cDNA) was synthesized
using an Omniscript RT kit (Qiagen, Valencia, CA) and
used for qPCR with SYBR green (Applied Biosystems, Inc.,
Foster City, CA) and Apoe primers (Forward: 5′ AACC
GCTTCTGGGATTACCTG 3′ and Reverse: 5′ TCAGTT
CTTGTGTGACTTGGGA 3′ from Primerdesign Ltd.,
Southampton, UK). The Apoe expression level was normal-
ized by Gapdh (Forward: 5′ TGGTGAAGGTCGGTGT
GAAC 3′ and Reverse: 5′ CAATGAAGGGGTCGTTGA
TGG 3′ from Primerdesign Ltd., Southampton, UK). Rela-
tive expression differences were obtained using LinRegPCR
(v11.0) [38] and the Relative Expression Software Tool
(REST©) [39].
In vitro assessment of cholesterol efflux capacity of serum
from macrophage foam cells
THP-1 and J774A.1 cells were purchased from American
Type Culture Collection (ATCC, Manassas, VA) and cul-
tured in ATCC-formulated DMEM based media and
RPMI-1640, respectively, at 5% CO2 atmosphere at 37°C.
Low passage cells (p0–2) were used throughout the
experiment. Both cell types were treated with 10 nM of
phorbol myristate acetate (PMA) to differentiate into mac-
rophages. As described previously [18], the differentiated
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esterol mimic (F-cholesterol) [40] and 50 μg/ml oxidized
LDL (Biomedical Technologies, Inc., Stoughton, MA) to
induce macrophage foam cell formation. The macro-
phage foam cells were used to perform a cell-based, high-
throughput screening assay for cholesterol efflux. Five μl
of serum was added in 100 μl of cell culture medium (n =
5 per strain) in triplicate and left for 48 hours for J774A.1
macrophage foam cells and 1 hour for THP-1 macrophage
foam cells. Fluorescent cholesterol mimic (F-cholesterol)
in cells and media was measured in separate wells at 485/
535 excitation/emission wavelengths. Cholesterol efflux
capacity (%) was calculated as F-cholesterol efflux (%) =
F-cholesterol in medium ∕ (F-cholesterol in medium +
F-cholesterol in cells) × 100.
Histological assessment of atherosclerotic fatty
streak volume
Fatty streak volume was assessed as previously described
[41] with minor modifications. In brief, 24-week-old Pcsk9
KO and control males were fed an atherogenic diet for
10 weeks. Supplementation of 0.5% cholic acid in the diet
increases intestinal cholesterol absorption, which then ac-
celerates atherosclerosis development. Hearts were col-
lected, embedded in optimal cutting temperature (OCT)
compound, sliced in 10-μm thick sections, placed on glass
slides and fixed in 10% formalin. Lipids and esterified cho-
lesterol were stained with oil red O and counter-stained
with Mayer’s hematoxylin [42]. Images of slides were digita-
lized using a Nanozoomer (Hamamatsu, Bridgewater, NJ).
To identify the identical histological region for all animals,
the area in the aortic sinus where the coronary artery and
ascending aorta join was used as a landmark. For each ani-
mal, individual digitalized images of 12 sections above and
12 sections below the landmark were loaded into FIJI (NIH,
Bethesda, WD) and saved as Z-stacks. These Z-stacks were
loaded into AutoAligner (Bitplane AG, Zürich, Switzerland)
to align sections and then opened in Imaris (Bitplane AG,
Zürich, Switzerland) to reconstruct 3-dimensional images
and calculate the average volume of atherosclerotic fatty
streak (mm3).
Statistics
All data represent the mean ± SEM from the number of
animals of each group. For comparisons of two groups,
levels of significance were calculated with the two-sample
t-test using JMP9 (SAS Institute, Inc., Cary, NC).
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